Login to Your Account



$25M Up Front, $125M Potential

Genzyme Purchasing Rights In Ceregene Parkinson's Deal

By Randall Osborne


Friday, June 22, 2007

West Coast Editor

Ceregene Inc. is keeping U.S. and Canadian rights to its Phase II drug for Parkinson's disease and getting $25 million up front plus as much as $125 million in milestone payments, along with 50 percent of worldwide Phase III costs covered, through a deal with Genzyme Corp, which will pay royalties on sales in other territories. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription